What is Epivax?
Headquartered in Providence, Rhode Island, Epivax is an American biotechnology firm specializing in immunoinformatics and immunogenicity risk assessment. The company serves as a vital bridge between advanced computational modeling and laboratory-based validation, enabling partners to optimize the safety and efficacy of vaccines and biologic drugs. By integrating AI-driven predictive tools with rigorous scientific analysis, Epivax effectively mitigates immune response risks, a critical factor in modern pharmaceutical development.
The firm's market position is defined by its unique ability to support the entire lifecycle of biologic development. Through its sophisticated suite of tools, Epivax assists pharmaceutical companies, academic institutions, and regulatory bodies in navigating the intricate challenges of immunogenicity. This dual-pronged approach—combining high-throughput computational analysis with empirical laboratory testing—positions the company as an indispensable asset in the global effort to improve health outcomes and accelerate the delivery of safe, effective therapeutics.
How much funding has Epivax raised?
Epivax has raised a total of $4.6M across 9 funding rounds:
Grant
$368K
Grant
$600K
Grant
$390K
Grant
$458K
Multiple Rounds
$1.9M
Grant
$600K
Debt
$350K
Grant (2007): $368K with participation from National Institutes of Health
Grant (2008): $600K led by National Institutes of Health
Grant (2008): $390K supported by National Institutes of Health
Grant (2011): $458K featuring National Institutes of Health
Grant (2012): $1.5M backed by National Institutes of Health
Grant (2012): $300K with participation from National Institutes of Health
Grant (2012): $55K led by GBS/CIDP Foundation International
Grant (2016): $600K supported by National Institutes of Health
Debt (2020): $350K featuring PPP
Key Investors in Epivax
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing foundational support for scientific innovation.
PPP
Public-Private Partnership
GBS/CIDP Foundation International
A global non-profit organization dedicated to supporting research and providing resources for individuals affected by Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy.
What's next for Epivax?
With the recent infusion of capital, Epivax is well-positioned to accelerate its research and development initiatives, particularly in the realm of next-generation vaccine design. The strategic focus will likely center on enhancing the predictive accuracy of its AI models and expanding its footprint in the biologics safety market. As the company moves into this next phase of growth, it is expected to deepen its integration with pharmaceutical pipelines, further cementing its role as a leader in computational immunology.
Looking ahead, the firm's ability to translate complex immunological data into actionable insights will be paramount. By continuing to foster high-level collaborations and investing in its core technology, Epivax is poised to address the evolving demands of the biotech sector, ensuring that its partners can navigate regulatory hurdles with greater speed and confidence while maintaining the highest standards of therapeutic safety.
